|
|
News Breaks
|
November 18, 2009
|
| 12:31 EDT |  | SNSS |
| theflyonthewall.com: | Sunesis Pharmaceuticals reports data from nonclinical studies of Voreloxin | | Sunesis Pharmaceuticals reported data from two nonclinical studies of voreloxin at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, which is being held in Boston, MA. In one study, clinical proof-of-mechanism is established in samples from patients treated with voreloxin in the Company's ongoing Phase 2 clinical study of voreloxin in combination with cytarabine in relapsed or refractory acute myeloid leukemia. In an additional study, voreloxin's synergistic and additive effects are demonstrated in combination with cytarabine, azacitidine, decitabine and clofarabine, agents which are currently used in the treatment of AML. Results from both of these studies support the current combination study and identify potential opportunities for further clinical evaluation. :theflyonthewall.com |
|
|
News For SNSS From The Last 14 Days Check below for free stories on SNSS the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 2, 2012
|
| 16:08 EDT | | SNSS |
|
|
|
|
|
Subscribe for More Information